{"id":919337,"date":"2025-12-12T14:40:55","date_gmt":"2025-12-12T19:40:55","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/notice-to-long-term-shareholders-of-cytokinetics-inc-nasdaq-cytk-fortrea-holdings-inc-nasdaq-ftre-synopsys-inc-nasdaq-snps-and-webtoon-entertainment-inc-nasdaq-wbtn-grabar-law-o\/"},"modified":"2025-12-12T14:40:55","modified_gmt":"2025-12-12T19:40:55","slug":"notice-to-long-term-shareholders-of-cytokinetics-inc-nasdaq-cytk-fortrea-holdings-inc-nasdaq-ftre-synopsys-inc-nasdaq-snps-and-webtoon-entertainment-inc-nasdaq-wbtn-grabar-law-o","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/notice-to-long-term-shareholders-of-cytokinetics-inc-nasdaq-cytk-fortrea-holdings-inc-nasdaq-ftre-synopsys-inc-nasdaq-snps-and-webtoon-entertainment-inc-nasdaq-wbtn-grabar-law-o\/","title":{"rendered":"Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Fortrea Holdings, Inc. (NASDAQ: FTRE); Synopsys, Inc. (NASDAQ: SNPS); and WEBTOON Entertainment Inc. (NASDAQ: WBTN): Grabar Law Office Investigates Claims on Your Behalf"},"content":{"rendered":"
\n

PHILADELPHIA, Dec. 12, 2025 (GLOBE NEWSWIRE) — <\/p>\n

\n
\n Cytokinetics, Inc. (NASDAQ: CYTK):<\/u>
\n <\/strong>\n <\/p>\n

Grabar Law Office is investigating claims on behalf of shareholders of Cytokinetics, Inc. (NASDAQ: CYTK). The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.<\/p>\n

\n If you purchased<\/strong>
\n Cytokinetics, Inc. (NASDAQ: CYTK) shares prior to <\/strong>
\n December 27, 2023,<\/strong>
\n and still hold shares today, <\/strong>
\n you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. Please visit <\/strong>
\n
\n https:\/\/grabarlaw.com\/the-latest\/cytokinetics-shareholder-investigation\/<\/strong>
\n <\/a>
\n , contact Joshua Grabar at <\/strong>
\n
\n jgrabar@grabarlaw.com<\/strong>
\n <\/a>
\n , <\/strong>
\n or call 267-507-6085.<\/strong>\n <\/p>\n

\n WHY? <\/strong>As alleged in a recently filed federal securities fraud class action complaint, Cytokinetics, Inc. (NASDAQ: CYTK), through certain of its officers made materially false and misleading statements on to the market, Specifically, on\u00a0March 10, 2025, Cytokinetics disclosed that the U.S. Food and Drug Administration (“FDA”) had decided not to convene an advisory committee meeting to review the Company’s New Drug Application (“NDA”) for aficamten. On\u00a0May 1, 2025, Cytokinetics announced that the FDA had extended the Prescription Drug User Fee Act action date for aficamten’s NDA from\u00a0September 26, 2025\u00a0to\u00a0December 26, 2025\u00a0in order to review a Risk Evaluation and Mitigation Strategy (“REMS”) submitted at the FDA’s request after the initial NDA filing, thereby disclosing that the Company had not included a REMS in the original NDA. Then, on\u00a0May 6, 2025, Chief Executive Officer\u00a0Robert I. Blum\u00a0acknowledged that Cytokinetics had multiple pre-NDA meetings with the FDA to discuss safety monitoring and risk mitigation but chose to submit the NDA without a REMS, relying on labeling and voluntary education materials. These misleading statements and delayed disclosures caused the company and its shareholders significant harm.<\/p>\n

\n WHAT YOU CAN DO NOW:<\/strong>
\n If you purchased<\/strong>
\n Cytokinetics, Inc. (NASDAQ: CYTK) shares prior to <\/strong>
\n December 27, 2023,<\/strong>
\n and still hold shares today, <\/strong>
\n you are encouraged to visit <\/strong>
\n
\n https:\/\/grabarlaw.com\/the-latest\/cytokinetics-shareholder-investigation\/<\/strong>
\n <\/a>
\n , contact Joshua Grabar at <\/strong>
\n
\n jgrabar@grabarlaw.com<\/strong>
\n <\/a>
\n , <\/strong>
\n or call 267-507-6085. You can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever.<\/strong> $CYTK #Cytokinetics #CYTK<\/p>\n

\n
\n Fortrea Holdings, Inc. (NASDAQ: FTRE)<\/u>
\n <\/strong>
\n :<\/strong>\n <\/p>\n

Grabar Law Office is investigating claims on behalf of shareholders of Fortrea Holdings, Inc. (NASDAQ: FTRE). The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.<\/p>\n

\n Current Fortrea Holdings, Inc. (NASDAQ: FTRE) shareholders who purchased or acquired Fortrea shares on or near the <\/strong>
\n July 3, 2023<\/strong>
\n Labcorp spinoff, and still hold shares today, <\/strong>
\n can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to them whatsoever. <\/strong>
\n
\n You are encouraged to visit <\/strong>
\n
\n https:\/\/grabarlaw.com\/the-latest\/fortrea-shareholder-investigation\/<\/strong>
\n <\/a>
\n , contact Joshua Grabar at <\/strong>
\n
\n jgrabar@grabarlaw.com<\/strong>
\n <\/a>
\n , <\/strong>
\n or call 267-507-6085. <\/strong>\n <\/p>\n

\n WHY?<\/strong> According to an underlying securities fraud class action complaint, Fortrea Holdings, Inc. (NASDAQ: FTRE), through certain of its officers, made materially false and misleading statements regarding the Company’s business, operations, and prospects. Specifically, the Complaint alleges Defendants made false and\/or misleading statements and\/or failed to disclose that: (i) Fortrea overestimated the amount of revenue the Labcorp Pre-Spin Projects were likely to contribute to the Company’s 2025 earnings; (ii) Fortrea overstated the cost savings it would likely achieve by exiting the TSAs; (iii) as a result, the Company’s previously announced EBITDA targets for 2025 were inflated; (iv) accordingly, the viability of the Company’s post-Spin-Off business model, as well as its business and\/or financial prospects, were overstated; and (v) as a result, the Company’s public statements were materially false and misleading at all relevant times.<\/p>\n

\n WHAT YOU CAN DO NOW:<\/strong>
\n If you purchased or acquired Fortrea Holdings, Inc. (NASDAQ: FTRE) shares on or near the <\/strong>
\n July 3, 2023<\/strong>
\n Labcorp spinoff<\/strong>
\n , <\/strong>
\n and still hold shares today, <\/strong>
\n you are encouraged to visit <\/strong>
\n
\n https:\/\/grabarlaw.com\/the-latest\/fortrea-shareholder-investigation\/<\/strong>
\n <\/a>
\n , contact Joshua Grabar at <\/strong>
\n
\n jgrabar@grabarlaw.com<\/strong>
\n <\/a>
\n , <\/strong>
\n or call 267-507-6085. You can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever.<\/strong> $FTRE #Fortrea<\/p>\n

\n
\n Synopsys, Inc. (NASDAQ: SNPS):<\/u>
\n <\/strong>\n <\/p>\n

Grabar Law Office is investigating claims on behalf of shareholders of Synopsys, Inc. (NASDAQ: SNPS). The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.<\/p>\n

\n If you purchased <\/strong>
\n Synopsys (NASDAQ: SNPS) shares prior to December 4, 2024, or acquired Synopsys shares <\/strong>
\n in<\/strong>
\n exchange for shares of Ansys, Inc. (\u201cAnsys\u201d) common stock<\/strong>
\n , <\/strong>
\n you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever.<\/strong>
\n Please visit <\/strong>
\n
\n https:\/\/grabarlaw.com\/the-latest\/synopsys-shareholder-investigation\/<\/strong>
\n <\/a>
\n , contact Joshua Grabar at <\/strong>
\n
\n jgrabar@grabarlaw.com<\/strong>
\n <\/a>
\n , <\/strong>
\n or call us at 267-507-6085. <\/strong>
\n \n <\/p>\n

\n WHY?<\/strong> As alleged in a recently filed underlying securities fraud class action complaint, on March 14, 2024, Synopsys (NASDAQ: SNPS) filed with the SEC a registration statement for the acquisition of ANSYS Inc. which was declared effective on April 17, 2024. On April 17, 2024, Synopsys filed with the SEC a prospectus for the Acquisition of ANSYS. The Acquisition Materials stated that ANSYS shareholders would receive $197.00 in cash and 0.345 shares of Synopsys common stock in exchange for each share of ANSYS they held at the time of the merger. Unbeknownst to investors, leading up to and at the time of the Acquisition, Synopsys\u2019 historical revenue and profit growth as represented in their Acquisition Materials were artificially inflated by the Company\u2019s unsustainable business practices. Specifically, it is alleged that Defendants misled investors by failing to disclose the following adverse facts: (1) the Company\u2019s growing emphasis on artificial intelligence (\u201cAI\u201d) customers, who require more customization, was weakening the economics of its Design IP business; (2) as a result, certain of the Company\u2019s road map and resource choices were unlikely to achieve their intended outcomes; (3) these issues were materially harming the Company\u2019s financial performance; and (4) as a result of the foregoing, Defendants\u2019 positive statements about the Company\u2019s business, operations, and prospects that when made were materially misleading and\/or lacked a reasonable basis.<\/p>\n

On September 9, 2025, Synopsys released its Q3 2025 results and acknowledged, for the first time that its Design IP business had \u201cunderperformed expectations,\u201d design IP revenue had fallen 8% year-over-year, and the Company would need to \u201cpivot\u201d its road map and IP resources toward stronger-growth areas. Synopsys also revealed that several anticipated IP deals had not materialized and that issues involving a major foundry customer had contributed to the shortfall. The market reacted swiftly on this news with the stock price plunging 35.8% overnight, falling from $604.37 to $387.78 per share, erasing billions in market capitalization.<\/p>\n

\n WHAT YOU CAN DO NOW:<\/strong>
\n If you purchased <\/strong>
\n Synopsys (NASDAQ: SNPS) shares prior to December 4, 2024, or acquired Synopsys shares <\/strong>
\n in<\/strong>
\n exchange for shares of Ansys, Inc. common stock<\/strong>
\n , <\/strong>
\n you are encouraged to visit <\/strong>
\n
\n https:\/\/grabarlaw.com\/the-latest\/synopsys-shareholder-investigation\/<\/strong>
\n <\/a>
\n , contact Joshua Grabar at <\/strong>
\n
\n jgrabar@grabarlaw.com<\/strong>
\n <\/a>
\n , <\/strong>
\n or call 267-507-6085. You can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever.<\/strong> $SNPS #Synopsys #SNPS<\/p>\n

\n
\n WEBTOON Entertainment Inc. (NASDAQ: WBTN) \u2013 Shareholder Class Action Survives Motion to Dismiss:<\/u>
\n <\/strong>\n <\/p>\n

Grabar Law Office is investigating claims on behalf of shareholders of WEBTOON Entertainment Inc. (NASDAQ: WBTN). The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.<\/p>\n

\n If you purchased WEBTOON (NASDAQ: WBTN) shares on or shortly after the Company\u2019s June 27, 2024 IPO, <\/strong>
\n you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever.<\/strong>\u00a0\u00a0 Please<\/strong> visit <\/strong>https:\/\/grabarlaw.com\/the-latest\/webtoon-shareholder-investigation\/<\/strong><\/a>, contact Joshua Grabar at <\/strong>jgrabar@grabarlaw.com<\/strong><\/a>, <\/strong>or call 267-507-6085. <\/strong><\/p>\n

\n WHY?<\/strong>
\n On November 14, 2025, the United States District Court for the Central District of California denied Defendants\u2019 attempt to dismiss an underlying securities fraud class action complaint.<\/strong> In allowing the class action to proceed, the court determined that Plaintiff adequately alleged that WEBTOON misled investors about the condition of one of its most critical performance metrics\u2014Monthly Active Users (\u201cMAU\u201d)\u2014at the time of its IPO. The Court also held that Plaintiff plausibly alleged that WEBTOON\u2019s risk disclosures and omission-based statements were misleading.<\/p>\n

\n WHAT YOU CAN DO NOW:<\/strong>
\n If you purchased WEBTOON (NASDAQ: WBTN) shares on or shortly after the Company\u2019s June 27, 2024 IPO, <\/strong>
\n you are encouraged to visit <\/strong>
\n
\n https:\/\/grabarlaw.com\/the-latest\/webtoon-shareholder-investigation\/<\/strong>
\n <\/a>
\n , contact Joshua Grabar at <\/strong>
\n
\n jgrabar@grabarlaw.com<\/strong>
\n <\/a>
\n , <\/strong>
\n or call 267-507-6085. You can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever.<\/strong> #WBTN #WEBTOON $WBTN<\/p>\n

\n Attorney Advertising Disclaimer<\/a>\n <\/p>\n

Contact:
Joshua H. Grabar, Esq.
Grabar Law Office
One Liberty Place
1650 Market Street, Suite 3600
Philadelphia, PA 19103
Tel: 267-507-6085
Email: jgrabar@grabarlaw.com<\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

PHILADELPHIA, Dec. 12, 2025 (GLOBE NEWSWIRE) — Cytokinetics, Inc. (NASDAQ: CYTK): Grabar Law Office is investigating claims on behalf of shareholders of Cytokinetics, Inc. (NASDAQ: CYTK). The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company. If you purchased Cytokinetics, Inc. (NASDAQ: CYTK) shares prior to December 27, 2023, and still hold shares today, you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. Please visit https:\/\/grabarlaw.com\/the-latest\/cytokinetics-shareholder-investigation\/ , contact Joshua Grabar at jgrabar@grabarlaw.com , or call 267-507-6085. WHY? As alleged in a recently filed federal securities fraud class action complaint, Cytokinetics, Inc. (NASDAQ: CYTK), through certain of its … <\/p>\n

Continue reading “Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Fortrea Holdings, Inc. (NASDAQ: FTRE); Synopsys, Inc. (NASDAQ: SNPS); and WEBTOON Entertainment Inc. (NASDAQ: WBTN): Grabar Law Office Investigates Claims on Your Behalf”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-919337","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nNotice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Fortrea Holdings, Inc. (NASDAQ: FTRE); Synopsys, Inc. (NASDAQ: SNPS); and WEBTOON Entertainment Inc. (NASDAQ: WBTN): Grabar Law Office Investigates Claims on Your Behalf - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/notice-to-long-term-shareholders-of-cytokinetics-inc-nasdaq-cytk-fortrea-holdings-inc-nasdaq-ftre-synopsys-inc-nasdaq-snps-and-webtoon-entertainment-inc-nasdaq-wbtn-grabar-law-o\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Fortrea Holdings, Inc. (NASDAQ: FTRE); Synopsys, Inc. (NASDAQ: SNPS); and WEBTOON Entertainment Inc. (NASDAQ: WBTN): Grabar Law Office Investigates Claims on Your Behalf - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PHILADELPHIA, Dec. 12, 2025 (GLOBE NEWSWIRE) — Cytokinetics, Inc. (NASDAQ: CYTK): Grabar Law Office is investigating claims on behalf of shareholders of Cytokinetics, Inc. (NASDAQ: CYTK). The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company. If you purchased Cytokinetics, Inc. (NASDAQ: CYTK) shares prior to December 27, 2023, and still hold shares today, you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. Please visit https:\/\/grabarlaw.com\/the-latest\/cytokinetics-shareholder-investigation\/ , contact Joshua Grabar at jgrabar@grabarlaw.com , or call 267-507-6085. WHY? As alleged in a recently filed federal securities fraud class action complaint, Cytokinetics, Inc. (NASDAQ: CYTK), through certain of its … Continue reading "Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Fortrea Holdings, Inc. (NASDAQ: FTRE); Synopsys, Inc. (NASDAQ: SNPS); and WEBTOON Entertainment Inc. (NASDAQ: WBTN): Grabar Law Office Investigates Claims on Your Behalf"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/notice-to-long-term-shareholders-of-cytokinetics-inc-nasdaq-cytk-fortrea-holdings-inc-nasdaq-ftre-synopsys-inc-nasdaq-snps-and-webtoon-entertainment-inc-nasdaq-wbtn-grabar-law-o\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-12T19:40:55+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYwMTU4MyM3MzIwMDQ4IzIyMDEyNzA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/notice-to-long-term-shareholders-of-cytokinetics-inc-nasdaq-cytk-fortrea-holdings-inc-nasdaq-ftre-synopsys-inc-nasdaq-snps-and-webtoon-entertainment-inc-nasdaq-wbtn-grabar-law-o\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/notice-to-long-term-shareholders-of-cytokinetics-inc-nasdaq-cytk-fortrea-holdings-inc-nasdaq-ftre-synopsys-inc-nasdaq-snps-and-webtoon-entertainment-inc-nasdaq-wbtn-grabar-law-o\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Fortrea Holdings, Inc. (NASDAQ: FTRE); Synopsys, Inc. (NASDAQ: SNPS); and WEBTOON Entertainment Inc. (NASDAQ: WBTN): Grabar Law Office Investigates Claims on Your Behalf\",\"datePublished\":\"2025-12-12T19:40:55+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/notice-to-long-term-shareholders-of-cytokinetics-inc-nasdaq-cytk-fortrea-holdings-inc-nasdaq-ftre-synopsys-inc-nasdaq-snps-and-webtoon-entertainment-inc-nasdaq-wbtn-grabar-law-o\\\/\"},\"wordCount\":1472,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/notice-to-long-term-shareholders-of-cytokinetics-inc-nasdaq-cytk-fortrea-holdings-inc-nasdaq-ftre-synopsys-inc-nasdaq-snps-and-webtoon-entertainment-inc-nasdaq-wbtn-grabar-law-o\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYwMTU4MyM3MzIwMDQ4IzIyMDEyNzA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/notice-to-long-term-shareholders-of-cytokinetics-inc-nasdaq-cytk-fortrea-holdings-inc-nasdaq-ftre-synopsys-inc-nasdaq-snps-and-webtoon-entertainment-inc-nasdaq-wbtn-grabar-law-o\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/notice-to-long-term-shareholders-of-cytokinetics-inc-nasdaq-cytk-fortrea-holdings-inc-nasdaq-ftre-synopsys-inc-nasdaq-snps-and-webtoon-entertainment-inc-nasdaq-wbtn-grabar-law-o\\\/\",\"name\":\"Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Fortrea Holdings, Inc. (NASDAQ: FTRE); Synopsys, Inc. (NASDAQ: SNPS); and WEBTOON Entertainment Inc. (NASDAQ: WBTN): Grabar Law Office Investigates Claims on Your Behalf - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/notice-to-long-term-shareholders-of-cytokinetics-inc-nasdaq-cytk-fortrea-holdings-inc-nasdaq-ftre-synopsys-inc-nasdaq-snps-and-webtoon-entertainment-inc-nasdaq-wbtn-grabar-law-o\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/notice-to-long-term-shareholders-of-cytokinetics-inc-nasdaq-cytk-fortrea-holdings-inc-nasdaq-ftre-synopsys-inc-nasdaq-snps-and-webtoon-entertainment-inc-nasdaq-wbtn-grabar-law-o\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYwMTU4MyM3MzIwMDQ4IzIyMDEyNzA=\",\"datePublished\":\"2025-12-12T19:40:55+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/notice-to-long-term-shareholders-of-cytokinetics-inc-nasdaq-cytk-fortrea-holdings-inc-nasdaq-ftre-synopsys-inc-nasdaq-snps-and-webtoon-entertainment-inc-nasdaq-wbtn-grabar-law-o\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/notice-to-long-term-shareholders-of-cytokinetics-inc-nasdaq-cytk-fortrea-holdings-inc-nasdaq-ftre-synopsys-inc-nasdaq-snps-and-webtoon-entertainment-inc-nasdaq-wbtn-grabar-law-o\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/notice-to-long-term-shareholders-of-cytokinetics-inc-nasdaq-cytk-fortrea-holdings-inc-nasdaq-ftre-synopsys-inc-nasdaq-snps-and-webtoon-entertainment-inc-nasdaq-wbtn-grabar-law-o\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYwMTU4MyM3MzIwMDQ4IzIyMDEyNzA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYwMTU4MyM3MzIwMDQ4IzIyMDEyNzA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/notice-to-long-term-shareholders-of-cytokinetics-inc-nasdaq-cytk-fortrea-holdings-inc-nasdaq-ftre-synopsys-inc-nasdaq-snps-and-webtoon-entertainment-inc-nasdaq-wbtn-grabar-law-o\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Fortrea Holdings, Inc. (NASDAQ: FTRE); Synopsys, Inc. (NASDAQ: SNPS); and WEBTOON Entertainment Inc. (NASDAQ: WBTN): Grabar Law Office Investigates Claims on Your Behalf\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Fortrea Holdings, Inc. (NASDAQ: FTRE); Synopsys, Inc. (NASDAQ: SNPS); and WEBTOON Entertainment Inc. (NASDAQ: WBTN): Grabar Law Office Investigates Claims on Your Behalf - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/notice-to-long-term-shareholders-of-cytokinetics-inc-nasdaq-cytk-fortrea-holdings-inc-nasdaq-ftre-synopsys-inc-nasdaq-snps-and-webtoon-entertainment-inc-nasdaq-wbtn-grabar-law-o\/","og_locale":"en_US","og_type":"article","og_title":"Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Fortrea Holdings, Inc. (NASDAQ: FTRE); Synopsys, Inc. (NASDAQ: SNPS); and WEBTOON Entertainment Inc. (NASDAQ: WBTN): Grabar Law Office Investigates Claims on Your Behalf - Market Newsdesk","og_description":"PHILADELPHIA, Dec. 12, 2025 (GLOBE NEWSWIRE) — Cytokinetics, Inc. (NASDAQ: CYTK): Grabar Law Office is investigating claims on behalf of shareholders of Cytokinetics, Inc. (NASDAQ: CYTK). The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company. If you purchased Cytokinetics, Inc. (NASDAQ: CYTK) shares prior to December 27, 2023, and still hold shares today, you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. Please visit https:\/\/grabarlaw.com\/the-latest\/cytokinetics-shareholder-investigation\/ , contact Joshua Grabar at jgrabar@grabarlaw.com , or call 267-507-6085. WHY? As alleged in a recently filed federal securities fraud class action complaint, Cytokinetics, Inc. (NASDAQ: CYTK), through certain of its … Continue reading \"Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Fortrea Holdings, Inc. (NASDAQ: FTRE); Synopsys, Inc. (NASDAQ: SNPS); and WEBTOON Entertainment Inc. (NASDAQ: WBTN): Grabar Law Office Investigates Claims on Your Behalf\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/notice-to-long-term-shareholders-of-cytokinetics-inc-nasdaq-cytk-fortrea-holdings-inc-nasdaq-ftre-synopsys-inc-nasdaq-snps-and-webtoon-entertainment-inc-nasdaq-wbtn-grabar-law-o\/","og_site_name":"Market Newsdesk","article_published_time":"2025-12-12T19:40:55+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYwMTU4MyM3MzIwMDQ4IzIyMDEyNzA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/notice-to-long-term-shareholders-of-cytokinetics-inc-nasdaq-cytk-fortrea-holdings-inc-nasdaq-ftre-synopsys-inc-nasdaq-snps-and-webtoon-entertainment-inc-nasdaq-wbtn-grabar-law-o\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/notice-to-long-term-shareholders-of-cytokinetics-inc-nasdaq-cytk-fortrea-holdings-inc-nasdaq-ftre-synopsys-inc-nasdaq-snps-and-webtoon-entertainment-inc-nasdaq-wbtn-grabar-law-o\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Fortrea Holdings, Inc. (NASDAQ: FTRE); Synopsys, Inc. (NASDAQ: SNPS); and WEBTOON Entertainment Inc. (NASDAQ: WBTN): Grabar Law Office Investigates Claims on Your Behalf","datePublished":"2025-12-12T19:40:55+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/notice-to-long-term-shareholders-of-cytokinetics-inc-nasdaq-cytk-fortrea-holdings-inc-nasdaq-ftre-synopsys-inc-nasdaq-snps-and-webtoon-entertainment-inc-nasdaq-wbtn-grabar-law-o\/"},"wordCount":1472,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/notice-to-long-term-shareholders-of-cytokinetics-inc-nasdaq-cytk-fortrea-holdings-inc-nasdaq-ftre-synopsys-inc-nasdaq-snps-and-webtoon-entertainment-inc-nasdaq-wbtn-grabar-law-o\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYwMTU4MyM3MzIwMDQ4IzIyMDEyNzA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/notice-to-long-term-shareholders-of-cytokinetics-inc-nasdaq-cytk-fortrea-holdings-inc-nasdaq-ftre-synopsys-inc-nasdaq-snps-and-webtoon-entertainment-inc-nasdaq-wbtn-grabar-law-o\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/notice-to-long-term-shareholders-of-cytokinetics-inc-nasdaq-cytk-fortrea-holdings-inc-nasdaq-ftre-synopsys-inc-nasdaq-snps-and-webtoon-entertainment-inc-nasdaq-wbtn-grabar-law-o\/","name":"Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Fortrea Holdings, Inc. (NASDAQ: FTRE); Synopsys, Inc. (NASDAQ: SNPS); and WEBTOON Entertainment Inc. (NASDAQ: WBTN): Grabar Law Office Investigates Claims on Your Behalf - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/notice-to-long-term-shareholders-of-cytokinetics-inc-nasdaq-cytk-fortrea-holdings-inc-nasdaq-ftre-synopsys-inc-nasdaq-snps-and-webtoon-entertainment-inc-nasdaq-wbtn-grabar-law-o\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/notice-to-long-term-shareholders-of-cytokinetics-inc-nasdaq-cytk-fortrea-holdings-inc-nasdaq-ftre-synopsys-inc-nasdaq-snps-and-webtoon-entertainment-inc-nasdaq-wbtn-grabar-law-o\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYwMTU4MyM3MzIwMDQ4IzIyMDEyNzA=","datePublished":"2025-12-12T19:40:55+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/notice-to-long-term-shareholders-of-cytokinetics-inc-nasdaq-cytk-fortrea-holdings-inc-nasdaq-ftre-synopsys-inc-nasdaq-snps-and-webtoon-entertainment-inc-nasdaq-wbtn-grabar-law-o\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/notice-to-long-term-shareholders-of-cytokinetics-inc-nasdaq-cytk-fortrea-holdings-inc-nasdaq-ftre-synopsys-inc-nasdaq-snps-and-webtoon-entertainment-inc-nasdaq-wbtn-grabar-law-o\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/notice-to-long-term-shareholders-of-cytokinetics-inc-nasdaq-cytk-fortrea-holdings-inc-nasdaq-ftre-synopsys-inc-nasdaq-snps-and-webtoon-entertainment-inc-nasdaq-wbtn-grabar-law-o\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYwMTU4MyM3MzIwMDQ4IzIyMDEyNzA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYwMTU4MyM3MzIwMDQ4IzIyMDEyNzA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/notice-to-long-term-shareholders-of-cytokinetics-inc-nasdaq-cytk-fortrea-holdings-inc-nasdaq-ftre-synopsys-inc-nasdaq-snps-and-webtoon-entertainment-inc-nasdaq-wbtn-grabar-law-o\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Fortrea Holdings, Inc. (NASDAQ: FTRE); Synopsys, Inc. (NASDAQ: SNPS); and WEBTOON Entertainment Inc. (NASDAQ: WBTN): Grabar Law Office Investigates Claims on Your Behalf"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/919337","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=919337"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/919337\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=919337"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=919337"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=919337"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}